Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001193125-25-283019·Lexeo Therapeutics, Inc.
Schedule 13G ownership disclosure
Lexeo Therapeutics Inc
Common Stock ($0.0001 par value) · CUSIP: 52886X107
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Longitude Capital Partners IV, LLC
Shares: 2,765,381 · Class: 3.8%
- Longitude Venture Partners IV, L.P.
Shares: 2,765,381 · Class: 3.8%
- Patrick G. Enright
Shares: 2,765,381 · Class: 3.8%
- Juliet Tammenoms Bakker
Shares: 2,765,381 · Class: 3.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-283019
- Form type
- SCHEDULE 13G/A
- Filer
- Lexeo Therapeutics, Inc.
- CIK
- CIK 1907108
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership